Logo image of ELYM

ELIEM THERAPEUTICS INC (ELYM) Stock Fundamental Analysis

NASDAQ:ELYM - Nasdaq - US28658R1068 - Common Stock - Currency: USD

5.11  -0.05 (-0.97%)

After market: 5.1 -0.01 (-0.2%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to ELYM. ELYM was compared to 571 industry peers in the Biotechnology industry. ELYM has a great financial health rating, but its profitability evaluates not so good. ELYM is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

ELYM had negative earnings in the past year.
ELYM had a positive operating cash flow in the past year.
ELYM had negative earnings in each of the past 5 years.
ELYM had a negative operating cash flow in each of the past 5 years.
ELYM Yearly Net Income VS EBIT VS OCF VS FCFELYM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 -10M -20M -30M -40M -50M

1.2 Ratios

The Return On Assets of ELYM (-28.40%) is better than 70.77% of its industry peers.
Looking at the Return On Equity, with a value of -28.88%, ELYM belongs to the top of the industry, outperforming 80.11% of the companies in the same industry.
Industry RankSector Rank
ROA -28.4%
ROE -28.88%
ROIC N/A
ROA(3y)-31.78%
ROA(5y)-44.63%
ROE(3y)-32.97%
ROE(5y)-48.21%
ROIC(3y)N/A
ROIC(5y)N/A
ELYM Yearly ROA, ROE, ROICELYM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 -20 -40 -60 -80 -100

1.3 Margins

ELYM does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ELYM Yearly Profit, Operating, Gross MarginsELYM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023

More info and screens

8

2. Health

2.1 Basic Checks

Compared to 1 year ago, ELYM has more shares outstanding
There is no outstanding debt for ELYM. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ELYM Yearly Shares OutstandingELYM Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 5M 10M 15M 20M 25M
ELYM Yearly Total Debt VS Total AssetsELYM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 50M 100M 150M

2.2 Solvency

An Altman-Z score of 53.84 indicates that ELYM is not in any danger for bankruptcy at the moment.
ELYM's Altman-Z score of 53.84 is amongst the best of the industry. ELYM outperforms 98.06% of its industry peers.
There is no outstanding debt for ELYM. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 53.84
ROIC/WACCN/A
WACCN/A
ELYM Yearly LT Debt VS Equity VS FCFELYM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 50M 100M 150M

2.3 Liquidity

A Current Ratio of 60.41 indicates that ELYM has no problem at all paying its short term obligations.
ELYM's Current ratio of 60.41 is amongst the best of the industry. ELYM outperforms 100.00% of its industry peers.
ELYM has a Quick Ratio of 60.41. This indicates that ELYM is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 60.41, ELYM belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 60.41
Quick Ratio 60.41
ELYM Yearly Current Assets VS Current LiabilitesELYM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 50M 100M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for ELYM have decreased strongly by -27.15% in the last year.
EPS 1Y (TTM)-27.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-851.87%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, ELYM will show a very strong growth in Earnings Per Share. The EPS will grow by 23.41% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y60%
EPS Next 2Y23.41%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ELYM Yearly Revenue VS EstimatesELYM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025
ELYM Yearly EPS VS EstimatesELYM Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 -2 -4 -6

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

ELYM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ELYM is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ELYM Price Earnings VS Forward Price EarningsELYM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ELYM Per share dataELYM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2 3

4.3 Compensation for Growth

A more expensive valuation may be justified as ELYM's earnings are expected to grow with 23.41% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y23.41%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

ELYM does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ELIEM THERAPEUTICS INC

NASDAQ:ELYM (10/2/2024, 8:06:17 PM)

After market: 5.1 -0.01 (-0.2%)

5.11

-0.05 (-0.97%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-04 2024-03-04/amc
Earnings (Next)N/A N/A
Inst Owners84.1%
Inst Owner Change-93.19%
Ins Owners7.95%
Ins Owner Change0.07%
Market Cap342.68M
Analysts43.33
Price Target4.59 (-10.18%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF 6230.48
P/B 1.54
P/tB 1.54
EV/EBITDA N/A
EPS(TTM)-2.15
EYN/A
EPS(NY)-0.63
Fwd EYN/A
FCF(TTM)-0.07
FCFYN/A
OCF(TTM)0
OCFY0.02%
SpS0
BVpS3.31
TBVpS3.31
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -28.4%
ROE -28.88%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-31.78%
ROA(5y)-44.63%
ROE(3y)-32.97%
ROE(5y)-48.21%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score7
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 60.41
Quick Ratio 60.41
Altman-Z 53.84
F-Score7
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-27.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-851.87%
EPS Next Y60%
EPS Next 2Y23.41%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-110.49%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y89.93%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y100.12%
OCF growth 3YN/A
OCF growth 5YN/A